Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **T-cell surface glycoprotein CD3 epsilon chain (CD3E)** is one of four distinct polypeptide chains (epsilon, gamma, delta, and zeta) forming the **CD3 complex**, which is essential for the surface expression and signaling function of the T cell receptor (TCR) in T lymphocytes[1][2][5][6]. CD3E contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic tail, which relays signal transduction from the antigen-engaged TCR to intracellular signaling pathways, thus playing a pivotal role in T cell activation, development, and immune responses[1][6]. Loss or mutation of the CD3E gene causes severe immunodeficiency, and CD3E is a well-established therapeutic and diagnostic target, notably for monoclonal antibody therapies that modulate T cell activity in contexts such as transplantation, autoimmune disease, and hematological cancers[5][6].
Monoclonal antibodies binding to CD3 epsilon induce T cell receptor modulation and T cell apoptosis or anergy - Block or modulate T-cell activation - Deplete T cells or modulate T cell function via Fc-mediated cytotoxic effects
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell surface glycoprotein CD3 epsilon chain (CD3E).